Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. - Wikidata - awgldk - TriplyDB

Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy.

Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy.

http://www.wikidata.org/entity/Q37156268

about

Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy.Biliary excretion of imatinib and its active metabolite CGP74588 during severe hepatic dysfunction.High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis.Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.Erlotinib and pantoprazole: a relevant interaction or not?Retrospective evaluation of methotrexate elimination when co-administered with proton pump inhibitors Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors.Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: A retrospective cohort study Drug interactions in childhood cancer.Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients.Preventing and Managing Toxicities of High-Dose Methotrexate The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus.Drug interactions in metastatic breast cancer.Pharmacokinetic drug-drug interactions with methotrexate in oncology.Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib.Adverse drug reactions due to drug-drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method.Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.Renal Drug Transporters and Drug Interactions.A Comparison of Alkaline Water and Mediterranean Diet vs Proton Pump Inhibition for Treatment of Laryngopharyngeal Reflux.Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia.Evaluation of para-Aminosalicylic Acid as a Substrate of Multiple Solute Carrier Uptake Transporters and Possible Drug Interactions with Nonsteroidal Anti-inflammatory Drugs In Vitro.Glucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicity.High-dose methotrexate in adult oncology patients: a case-control study assessing the risk association between drug interactions and methotrexate toxicity.Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2.Clinical pharmacology in everyday clinical care.Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance.Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3.Drug Repositioning of Proton Pump Inhibitors for Enhanced Efficacy and Safety of Cancer Chemotherapy.Effects of Concomitant Medication Use on Gefitinib-Induced Hepatotoxicity.Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients.Lansoprazole Exacerbates Pemetrexed-Mediated Hematologic Toxicity by Competitive Inhibition of Renal Basolateral Human Organic Anion Transporter 3.

P2860

Q26865927-62D3C6F4-4033-4BBA-A4B4-2409C4879976 Q33401038-6102B832-2B56-43B0-9D98-E39B920D9D43 Q33557148-691F9FB3-2A8C-45DF-9BBC-D5240E6A4D8F Q33908105-4063F22E-6760-4E40-82E2-33D5C3C77582 Q33909887-ED579440-4511-45C7-9232-B061BB0CD0F5 Q34065294-6B458B27-F57C-4A66-9979-A6C449FE1E68 Q34457467-2032541E-7D40-4FAF-BF2B-8457D5999557 Q34571060-6F973865-0951-492C-B882-0E43F917F8FC Q34871636-483FF670-498B-4389-B288-B70760865564 Q35913249-DBC8A73F-11A7-43DE-B159-28B4B7DB1A99 Q36269700-138A323E-3944-429F-99AB-9A3188AEAF89 Q36898141-D6060A71-AFF5-417F-A27D-1D47495C0919 Q37373153-BFF7063F-33F0-47ED-B10A-1F605C07B5EB Q37496637-1FC6A22E-BC34-41D4-95DD-B14988747FF5 Q37709906-0257C7FF-09A2-457C-9CAB-F7A3933311BE Q37791284-142CD899-0599-4C4D-A6FD-CAE54C5BCCCD Q37960131-A70CE716-4E8E-44C9-B789-FEC01AEDCADC Q38150978-AA762E23-772C-415A-8E46-F4F450803A48 Q38658675-29AB64AC-F7BF-4499-B18F-F2BF746DBA17 Q38865456-77AFF9F7-0435-4E8F-8116-203DC8CB453A Q39140289-E60C076F-4A88-43BA-B2BB-AA7BCD711003 Q40053716-2F8AD392-66FC-4A73-A46B-5F9782D20F7D Q41404243-5B917D79-A000-44DF-BCFF-7AA5F5634A37 Q42358808-3AB38E8F-2FF9-49A4-8CBE-AEA55C834259 Q43260573-36EA4F81-0EAA-486C-97A9-D04099C7929A Q43924069-E6D6C4E5-DAE0-4D47-9386-018551E5DE02 Q44639286-4D5C1FE8-A646-4707-8B82-EC777B27917F Q45142665-B22D0FD7-A5D9-4BD3-89FD-DD25A9F15027 Q46446111-573D580D-B8A7-4136-8B72-EFE854FDC4A6 Q47250639-82A7F206-FD1B-42FD-B366-A5C574F3DFC2 Q48249474-931A89DF-098B-4087-BF1D-9756B144F7E6 Q49215917-F596039B-C585-40B0-80E4-14CA4E978558 Q49582579-7550FA94-73E2-44C4-94A3-CD3F997A26CA Q51012681-D4E384EA-5714-4118-BD3C-430F804EF302 Q51350287-95978846-B480-4C21-B990-F26F55393DC2 Q53052634-A1921080-F0E2-4401-9A55-5607B219742F

P2860

Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy.

http://www.wikidata.org/entity/Q37156268

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Co-administration of proton pu ...... igh-dose methotrexate therapy.

@en

Co-administration of proton pu ...... igh-dose methotrexate therapy.

@nl

type

label

Co-administration of proton pu ...... igh-dose methotrexate therapy.

@en

Co-administration of proton pu ...... igh-dose methotrexate therapy.

@nl

prefLabel

Co-administration of proton pu ...... igh-dose methotrexate therapy.

@en

Co-administration of proton pu ...... igh-dose methotrexate therapy.

@nl

P1433

Q37156268-B79031EF-D235-43CE-A28A-012363FEB70B

P1476

Q37156268-7D70EFBC-F5EA-4EAA-AD2A-5AC8F404A724

P2093

Q37156268-3E947D89-1460-4D89-8030-C522445CF4D3

Q37156268-48E67715-D8A2-48F5-AC24-9041EB80927D

Q37156268-56A3694D-A879-4E08-954C-A89B9EF4FFD2

Q37156268-63B74D7C-DDA7-497A-867B-416FB1B40675

Q37156268-7EB91FBB-19A2-4260-803A-6703D57B48CC

Q37156268-E5D53233-6D17-4D5A-89E5-6CA1E70D3751

Q37156268-F8F9898A-E76F-45E4-924D-CCD994B82BA5

P2860

Q37156268-050C4010-83F6-4063-A7D8-6DB26A42011B

Q37156268-414F4600-FF2B-45A3-A43F-0BD4FD001C19

Q37156268-5A1183C1-E624-4205-AB1B-058D6BC92D2B

Q37156268-5C408ABE-D722-47EC-8496-BF4683390ED4

Q37156268-64F673B3-E0CE-4724-8F15-6DCDC0B24C8F

Q37156268-6724A8E9-1716-479A-8EBA-D15EB46D3292

Q37156268-766A3FCF-AA27-4B04-8E78-23EB7723775E

Q37156268-7CE1D4B1-236A-440B-AB74-D35104813488

Q37156268-CBA6F803-F7C2-48E0-9E06-6639254BBA24

Q37156268-D770ECD1-D4E2-4F47-81D0-AA907A528AC9

P304

Q37156268-493A6EF5-4E85-4A0D-8F16-36CF0AF5536E

P31

Q37156268-6371BBBA-45A1-4F06-AA35-635E7DF56CCE

P356

Q37156268-82212457-D746-4405-BE1A-69A6A7BB8F8C

P407

Q37156268-DBFF376F-CB72-49ED-AA97-647F1E25DB93

P433

Q37156268-9862ED5B-1295-4815-86CE-7A041C116EC2

P478

Q37156268-5D8627EC-00C1-4BE5-A9CB-25ECF69F0F50

P50

Q37156268-8D9D1023-A1EB-4F91-BDFE-FE5D45B016AD

P577

Q37156268-05F0704C-554A-460D-B6C4-9FAD5E60CBEC

P5875

Q37156268-94BB7422-6CDB-4D99-A42A-E06367B6815B

P698

Q37156268-C4AE9672-A294-460C-A775-F3D6220D30A8

P932

Q37156268-C93D694A-102D-4CDA-A22E-3786E704AE3F

P356

J.1365-2125.2008.03303.X

P1433

British Journal of Clinical Pharmacology

P1476

Co-administration of proton pu ...... high-dose methotrexate therapy

@en

P2093

Hirofumi Tamaki

http://www.w3.org/2001/XMLSchema#string

Kosuke Doki

http://www.w3.org/2001/XMLSchema#string

Kunihiro Suzuki

http://www.w3.org/2001/XMLSchema#string

Masato Homma

http://www.w3.org/2001/XMLSchema#string

Satoko Hori

http://www.w3.org/2001/XMLSchema#string

Yasufumi Sawada

http://www.w3.org/2001/XMLSchema#string

Yukinao Kohda

http://www.w3.org/2001/XMLSchema#string

P2860

Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole.

Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.

Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development.

Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices.

Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.

The pharmacology and clinical use of methotrexate.

Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.

Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity.

[Massive dose methotrexate with citrovorum factor rescue: MTX-pharmacokinetics, excretion pattern, and techniques for safety administration (author's transl)].

Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen.

P304

44-49

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2125.2008.03303.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P50

Hisakazu Ohtani

P577

2008-11-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23657034

http://www.w3.org/2001/XMLSchema#string

P698

19076159

http://www.w3.org/2001/XMLSchema#string

P932

2668083

http://www.w3.org/2001/XMLSchema#string